Ultralow Dose PET Imaging for 18F-NaF Uptake
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-120
SponsorAkiva Mintz
About this trial
The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET imaging) technique for increased bone turnover that is found in diseases such as cancer, trauma, infection, arthritis, and other benign diseases of bone detection and monitoring. The main question it aims to answer is:
Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called Fluorine-18 (18F)-sodium fluoride (NaF) and be imaged on a new type of high sensitivity PET scanner for up to 3 hours.
Eligibility criteria
Qualifiers
Age ≥18 years.
Ability to provide informed consent and comply with study procedures.
For female participants: Must not be pregnant or breastfeeding; Negative pregnancy test required for women of childbearing potential.
Disqualifiers
Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 millisievert [mSv] total).
More than four prior enrollments in this study.
Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan
Medication & Prior Treatment Exclusions
Trial design
Treatments tested in this trial
- 18F-NaF
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
Akiva Mintz
Lead sponsor
Nuclear Imaging Institute
Sponsor institution
Source ClinicalTrials.gov